Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels

Aug 19, 2021
  • In addition to the Company’s eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular surgeries at seven hospitals across the U.S.
  • Video testimonial features patient who experienced a traumatic leg injury and received the HAV to restore blood flow to her crushed limb

DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioengineered blood vessel, the Human Acellular Vessel (HAV), in the U.S.

Under the EAP, the HAV has been used for patients with emergency vascular conditions including peripheral arterial disease (PAD) and vascular trauma, for which there are limited treatment options. The HAV is an investigational product candidate and is not currently approved for sale by the FDA or any international regulatory authority. The HAV is being evaluated in multiple international multicenter clinical trials in vascular trauma, arteriovenous access for dialysis, and peripheral arterial disease (PAD), with over 450 HAV implants to date.

In the most recent EAP case reported, the HAV successfully restored perfusion to the leg in a bypass operation in a patient suffering from severe PAD and at risk of losing a leg due to poor blood flow. The Company also reported the story of a patient participating in Humacyte’s HAV Phase 2/3 trial for vascular trauma who received the HAV to repair a severe workplace injury. This patient, a longshoreperson who experienced a traumatic leg injury from an accident involving a shipyard crane, was at risk of losing her leg due to extensive damage from the crush injury. The patient received the HAV to restore blood flow to her crushed limb and avoid amputation. The patient’s story can be viewed here:

“When the artery can’t be repaired, we want to replace it with something that’s going to perform off the shelf like the patient’s own tissue,” said Michael Curi, M.D., MPA, Rutgers New Jersey Medical School Division of Vascular Surgery, and site principal investigator in the Phase 2/3 trial of the HAV for vascular trauma and the Phase 3 trials of the HAV for dialysis access. “Humacyte’s bioengineered HAVs may be one of the key scientific breakthroughs of our time and have the potential to significantly change our patterns of treatment and be an important option for vascular surgeons to have in their armamentarium.”

“The HAV has the potential to transform the care of patients with life- and limb-threatening conditions. While our primary focus is on the progress, integrity and successful completion of our controlled clinical trials to secure regulatory approval, we also perform our duty to provide expanded access for eligible patients with acute medical problems,” said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. “Our robust EAP work also further demonstrates the utility and versatility of the HAV, and offers patients with critical vascular issues a limb-saving alternative.”

For more information about Humacyte’s EAP for HAV, visit

On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement. On August 24, 2021, AHAC will hold a special shareholder’s meeting to vote on the proposed business combination with Humacyte.

About HAV
Human Acellular Vessels (HAV) are engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement – it can be manufactured at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic, infection-resistant, and can become durable living tissue. HAV is currently being evaluated in two Phase 3 trials in AV access and a Phase 2/3 trial for vascular trauma, and has been used in more than 430 patient implantations. It is the first product to receive Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration, and has also received FDA Fast Track designation.

About Humacyte
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit

About Alpha Healthcare Acquisition Corp.
Alpha Healthcare Acquisition Corp. (ticker: AHAC) is a special purpose acquisition company formed for the purpose of effecting a business combination with one or more businesses in the healthcare sector (“AHAC”). The company was founded by Mr. Rajiv Shukla who has two decades of buyouts, investments and operations experience in the healthcare industry. Mr. Shukla previously served as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp., a Nasdaq-listed special purpose acquisition company, that merged with DermTech, Inc (ticker: DMTK) in August 2019. On February 17, 2021, AHAC announced a definitive agreement to merge with Humacyte, Inc. along with a concurrent fully committed PIPE placement of $175 million of AHAC common shares at a price of $10.00 per share.

Important Information About the Merger and Special AHAC Special Shareholder Meeting
The Special Meeting will be held virtually via webcast at 10:00 a.m. EDT on August 24, 2021, and can be accessed by visiting: Shareholders can attend the Special Meeting using the meeting instructions outlined in AHAC’s definitive proxy statement. Shareholders of record as of the close of business on July 21, 2021, will be entitled to vote their shares at the Special Meeting. AHAC has engaged Morrow Sodali LLC as its proxy solicitor in connection with the Special Meeting and shareholders requiring assistance in voting can contact their broker or Morrow Sodali LLC for assistance, at (800) 662-5200. The AHAC Board of Directors unanimously recommends that shareholders vote "FOR" the Business Combination with Humacyte as well as the other proposals set forth in the proxy statement.

The proxy statement and AHAC’s other reports filed with the Securities and Exchange Commission (“SEC”) can be obtained, without charge, by directing a request to: The definitive proxy statement/prospectus included in AHAC’s registration statement on Form S-4 can also be obtained, without charge, at the SEC’s website (

A full description of the terms of the business combination is provided in the definitive proxy statement/prospectus included in AHAC’s registration statement on Form S-4 filed with the SEC. AHAC urges its investors, shareholders, and other interested persons to read the proxy statement/ prospectus as well as other documents filed with the SEC because these documents will contain important information about AHAC, Humacyte and the business combination. 

Participants in the Solicitation
AHAC and Humacyte and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the proposed business combination described in this press release under the rules of the SEC. Information about the directors and executive officers of AHAC is set forth in AHAC’s final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the “Securities Act”) on September 17, 2020, and is available free of charge at the SEC’s website at or by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5th Floor, New York, New York 10036. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the AHAC shareholders in connection with the proposed business combination is set forth in the registration statement containing the proxy statement/prospectus for the proposed business combination. These documents can be obtained free of charge from the sources indicated above.

Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing, progress, and results of our clinical trials; the anticipated characteristics and performance of our HAVs, our ability to successfully complete, clinical trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the commercialization of our HAVs and our ability to manufacture at commercial scale; the implementation of our business model, strategic plans for our business; the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology; the timing or likelihood of regulatory filings and approvals; timing, scope, and rate of reimbursement for our HAVs; our estimated available market opportunity; the proposed business combination, including the timing and structure of the business combination, the proceeds of the business combination, and the benefits of the business combination. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the ability to complete the business combination due to the failure to obtain approval from AHAC’s shareholders or satisfy other closing conditions in the Business Combination Agreement, the occurrence of any event that could give rise to the termination of the Business Combination Agreement, the ability to recognize the anticipated benefits of the business combination, the outcome of any legal proceedings that may be instituted against AHAC or Humacyte following announcement of the proposed business combination and related transactions, the impact of COVID-19 on Humacyte’s business and/or the ability of the parties to complete the business combination, the ability to obtain or maintain the listing AHAC’s common stock on Nasdaq following the proposed business combination, costs related to the proposed business combination, changes in applicable laws or regulations, the possibility that AHAC or Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those included under the header “Risk Factors” in the registration statement on Form S-4 filed by AHAC with the SEC and those included under the header “Risk Factors” in the final prospectus of AHAC related to its initial public offering. Most of these factors are outside of AHAC’s and Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

Humacyte Investor Contact:

Humacyte Media Contact:

A video accompanying this announcement is available at